New findings point to potential therapy for Parkinson's Disease

December 19, 2017 by Anna Williams, Northwestern University
Partial inhibition of the interaction between calcineurin and FKBP12, with low doses of the FDA-approved compound Tacrolimus, protect neurons against the toxic effects of a-synuclein, a protein critically implicated in Parkinson’s disease. Credit: Northwestern University

A new study, published in Proceedings of the National Academy of Sciences (PNAS), sheds light on a mechanism underlying Parkinson's disease and suggests that Tacrolimus—an existing drug that targets the toxic protein interaction explored in the study—could be used as a novel treatment.

Gabriela Caraveo Piso, Ph.D., assistant professor of Neurology in the Division of Movement Disorders, was the first and corresponding author of the study.

Parkinson's disease is a progressive neurological disorder marked by the loss of . There is no cure, and current treatments to help control the symptoms of Parkinson's—including tremor, slow movement and loss of balance—are limited.

Although the fundamental cause of Parkinson's disease is unknown, dysfunction of a protein called alpha-synuclein has long been thought to play an important role.

Previous investigations by Caraveo Piso and collaborators had established that increased of an enzyme called is associated with the alpha-synuclein toxicity seen in Parkinson's.

In the current study, the scientists built upon those discoveries to demonstrate, for the first time, that a protein called FKBP12 is a major regulator of calcineurin activity, and thus contributes to alpha-synuclein toxicity.

"Our new mechanistic findings have revealed that FKBP12 is the protein that tunes calcineurin activity," Caraveo Piso said. "It's very reminiscent of the Goldilocks story: In the context of alpha-synuclein, both too much and no calcineurin activity are detrimental—but an intermediate level of activity is protective."

The scientists also investigated whether reducing the functional interaction between calcineurin and FKBP12 might be protective against toxicity in vivo.

To do so, they employed an already well-established, FDA-approved inhibitor of this interaction, called Tacrolimus. The drug is currently used clinically in high doses to prevent organ rejection after a transplant, a process in which calcineurin also plays a critical role.

In an animal model of Parkinson's , the investigators demonstrated that Tacrolimus—when administered in low doses to achieve partial reduction of calcineurin activity—led to improvements in the functional features of dopaminergic neurons, and hence behavioral phenotypes.

Caraveo Piso noted that the discovery has strong potential for future clinical applications.

"We provide robust animal evidence for a feasible treatment against Parkinson's by repurposing Tacrolimus at low, sub-immunosuppressive doses," Caraveo Piso said. "Since Tacrolimus has high brain penetrance and can be given safely, a clinical trial of Tacrolimus in patients with early-stage Parkinson's would likely pose no serious logistical or regulatory difficulties."

The findings might also have implications for other related neurological diseases, such as Alzheimer's, Caraveo Piso notes, an area where calcineurin also plays an important role.

Explore further: Tug of war between Parkinson's protein and growth factor

More information: Gabriela Caraveo et al. FKBP12 contributes to α-synuclein toxicity by regulating the calcineurin-dependent phosphoproteome, Proceedings of the National Academy of Sciences (2017). DOI: 10.1073/pnas.1711926115

Related Stories

Tug of war between Parkinson's protein and growth factor

September 18, 2017
Alpha-synuclein, a sticky and sometimes toxic protein involved in Parkinson's disease (PD), blocks signals from an important brain growth factor, Emory researchers have discovered.

Drug discovery: Alzheimer's and Parkinson's spurred by same enzyme

July 3, 2017
Alzheimer's disease and Parkinson's disease are not the same. They affect different regions of the brain and have distinct genetic and environmental risk factors.

A new insight into Parkinson's disease protein

July 28, 2017
Abnormal clumps of certain proteins in the brain are a prominent feature of Parkinson's and other neurodegenerative diseases, but the role those same proteins might play in the normal brain has been unknown.

Researchers find new path to promising Parkinson's treatment

September 19, 2017
Three researchers at The University of Alabama are part of work that is leading to a new direction for drug discovery in the quest to treat Parkinson's disease.

Parkinson's is partly an autoimmune disease, study finds

June 21, 2017
Researchers have found the first direct evidence that autoimmunity—in which the immune system attacks the body's own tissues—plays a role in Parkinson's disease, the neurodegenerative movement disorder. The findings raise ...

Balance and movement improved in animal model of Parkinson's disease

June 12, 2017
Researchers at UCLA have developed a molecular compound that improves balance and coordination in mice with early stage Parkinson's disease. Further, the drug, called CLR01, reduced the amount of a toxic protein in the brain ...

Recommended for you

Researchers trace Parkinson's damage in the heart

July 13, 2018
A new way to examine stress and inflammation in the heart will help Parkinson's researchers test new therapies and explore an unappreciated way the disease puts people at risk of falls and hospitalization.

Study raises doubts on a previous theory of Parkinson's disease

July 6, 2018
Parkinson's disease was first described by a British doctor more than 200 years ago. The exact causes of this neurodegenerative disease are still unknown. In a study recently published in eLife, a team of researchers led ...

Drug protects neurons in Parkinson's disease

June 27, 2018
Systemic treatment of animal models with israpidine, a calcium channel inhibitor, reduced mitochondrial stress that might cause Parkinson's disease, according to a Northwestern Medicine study published in the Journal of Clinical ...

Half of those on Parkinson's drugs may develop impulse control problems

June 20, 2018
Over time, half of the people taking certain drugs for Parkinson's disease may develop impulse control disorders such as compulsive gambling, shopping or eating, according to a study published in the June 20, 2018, online ...

New evidence sheds light on how Parkinson's disease may happen

June 14, 2018
Researchers at Baylor College of Medicine and Texas Children's Hospital have identified unexpected new key players in the development of an early onset form of Parkinson's disease called Parkinsonism. These key players are ...

Scientists unravel molecular mechanisms of Parkinson's disease

June 12, 2018
Detailed brain cell analysis has helped researchers uncover new mechanisms thought to underlie Parkinson's disease.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.